Document is current

Any future updates will be listed below

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

Crossref DOI link: https://doi.org/10.1186/1471-2407-14-937

Published Online: 2014-12-11

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark